Adverse events201

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 201

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk
other	Anaemia	Blood and lymphatic system disorders	PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1	3
other	Anaemia	Blood and lymphatic system disorders	PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0	2
other	Anaemia	Blood and lymphatic system disorders	PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0	1
other	Lymph node pain	Blood and lymphatic system disorders	PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	0	3
other	Lymph node pain	Blood and lymphatic system disorders	PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	1	2
other	Lymph node pain	Blood and lymphatic system disorders	PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0	1
other	Vision blurred	Eye disorders	PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	1	3
other	Vision blurred	Eye disorders	PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0	2
other	Vision blurred	Eye disorders	PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0	1
other	Visual impairment	Eye disorders	PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	0	3
other	Visual impairment	Eye disorders	PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	1	2
other	Visual impairment	Eye disorders	PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0	1
other	Abdominal pain	Gastrointestinal disorders	PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	0	3
other	Abdominal pain	Gastrointestinal disorders	PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	0	2
other	Abdominal pain	Gastrointestinal disorders	PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	1	1
other	Constipation	Gastrointestinal disorders	PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	0	3
other	Constipation	Gastrointestinal disorders	PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	1	2
other	Constipation	Gastrointestinal disorders	PF-07901801 18 mg/kg + Tafasitamab + Lenalidomide	0	1
other	Diarrhoea	Gastrointestinal disorders	PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide	2	3
other	Diarrhoea	Gastrointestinal disorders	PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide	2	2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05626322/events

API reference For AI assistants

Adverse events201

Sources 3

Read this list from software.